Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155321 | 0.88 | LIPE (0.36) | LIPELMNASMN1; SMN2POLBMAPT | |
| SCHEMBL25191446 | 0.80 | LPL (0.44) | LPLLIPGKDM4EERN1 | |
| SCHEMBL29573177 | 0.80 | LIPE (0.40) | LIPELMNASMN1; SMN2 | |
| SCHEMBL24266097 | 0.80 | LIPE (0.40) | LIPELMNASMN1; SMN2 | |
| SCHEMBL30990845 | 0.80 | ALDH1A1 (0.38) | LIPELMNAMAPTF2F11 | |
| SCHEMBL28476218 | 0.80 | ALDH1A1 (0.37) | SMN1; SMN2POLBMAPTLPLLIPG | |
| SCHEMBL44941 | 0.80 | ALDH1A1 (0.38) | LIPELMNAMAPTF2F11 | |
| SCHEMBL13111262 | 0.78 | ALDH1A1 (0.37) | SMN1; SMN2POLBMAPTLPLLIPG | |
| SCHEMBL20536290 | 0.78 | LPL (0.38) | LIPEF2F11PRSS1PRSS2 | |
| SCHEMBL12542099 | 0.78 | LIPE (0.39) | LIPELMNAF2F11PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109996790-B | Piperazine carbamates and methods of making and using the same | H.隆德贝克有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2022040157-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | 5METIS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040157-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | 5METIS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3515897-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | ABHD6, RABL6, ABHD16A | LIPE 2080/4885LMNA 4625/4885SMN1; SMN2 2229/4885 |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | LIPE 2080/4885LMNA 4625/4885SMN1; SMN2 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.